Clik here to view.
Why do African Americans do better on Provenge than whites?
In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … At the...
View ArticleClik here to view.
Race and decision-making in prostate cancer management
An article in Oncology Nurse Advisor notes that “Black and white men prioritize certain treatment-related factors differently when considering prostate cancer treatment options.” Really? This should...
View ArticleClik here to view.
Does Test X change what physicians actually do and say to their patients?
One of the key ways in which we can (and do) assess the “value” of new types of medical test is by the degree to which they actually change the ways physicians act on the data and make decisions and/or...
View ArticleClik here to view.
New review article on mHSPC and mCRPC
Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic...
View ArticleClik here to view.
The “right” ways to treat TxN1M0 disease today
Really sound guidance on “the best” way to treat men who are initially diagnosed with lymph node-positive (TxN1M0) prostate cancer — or are found to have such cancer at the time of first-line surgery —...
View ArticleClik here to view.
The proposed, Finnish, ProScreen trial
A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial...
View ArticleClik here to view.
Chaarting direction after stampeding along the relevant latitude
So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and...
View ArticleClik here to view.
Salvage focal ablation for radio-recurrent prostate cancer
When there is a recurrence after primary radiation treatment, it is very tempting to try to identify the site(s) of local recurrence within the prostate and prostate bed and only treat those. The hope...
View ArticleClik here to view.
INO-5150 in early treatment of biochemically recurrent prostate cancer
In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and...
View ArticleClik here to view.
This may put the cat among the pigeons!
A large, newly published, observational study has suggested that comorbidity affects other-cause mortality but not prostate cancer-specific mortality after accounting for patient and tumor...
View ArticleClik here to view.
Axumin PET/CT scans change treatment recommendations in recurrent prostate...
The value of many cancer-related tests is actually based on whether the results of the particular test change the way that physicians plan to treat specific patients (hopefully for the better). On...
View ArticleClik here to view.
Should every prostate cancer patient be on a statin?
A recent article in the Journal of Clinical Oncology, together with an associated editorial, have addressed the issue of whether evidence is now sufficient to argue that all men with prostate cancer...
View ArticleClik here to view.
Repeated treatment with radium-223 after a first treatment cycle
Radium-223 or Xofigo was first approved in 2013 as “an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer,...
View ArticleClik here to view.
Patients’ understanding of the risks and benefits of first-line treatment
A newly published article in BJU International has (finally) proven something many prostate cancer educators and advocates have known for years: many patients have a very poor appreciation of the risks...
View ArticleClik here to view.
Germline genetics and different responses to different types of ADT
Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen...
View ArticleA specific subset of men with a specific genetic variation respond to...
Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer...
View ArticlePersonality and its impact on prostate cancer and its treatment
Your sitemaster is going to write this commentary with as much tact as he can muster but he is aware that this is going to be a very sensitive subject for some readers to deal with. Some of us are...
View ArticleMen initially diagnosed with de novo metastatic prostate cancer are living...
A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but...
View ArticleUnderstanding genetics, genomics, and their utility in prostate cancer
Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA)....
View ArticleWhy is this debate still going on at all?
The question between different types of physician as to whether radiation therapy or surgery is “better” for the first-line, curative treatment of localized prostate cancer has now been debated (over...
View Article